ATXA Publications & Posters

Conference Posters

​

The thromboxane receptor antagonist NTP42 improves haemodynamics, inhibits remodelling, and restores function within the cardiopulmonary system in preclinical pulmonary arterial hypertension models

​

European Society of Cardiology Congress 2021 - The Digital Experience - August 2021

​

​

NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension

​

European Respiratory Society International Congress - Madrid, Spain - September/October 2019

​

​

Efficacy of the novel thromboxane receptor antagonist NTP42 alone, or in combination with Sildenafil, in the Sugen/hypoxia-induced model of pulmonary arterial hypertension

​

European Society of Cardiology World Congress - Paris, France - August/September 2019

Publications

Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension

​

European Journal of Pharmacology - December 2020

​

​

NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

​

BMC Pulmonary Medicine - April 2020

​

​

Differential expression of the TPα and TPβ isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for FOXP1 in the transcriptional regulation of TPβ during monocyte-macrophage differentiation

​

Experimental and Molecular Pathology - October 2019

​

​

Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension

​

Cardiovascular Research - July 2018